BioStock: CombiGene has chosen CRO for the pain project

Report this content

CombiGene has chosen Charles River Laboratories as a partner for the peptide-based pain project COZY01, which is being conducted in collaboration with Zyneyro. Charles River will perform the preclinical toxicology studies required to start the first human studies in the COZY01 project.

Read the article at biostock.se:

CombiGene has chosen CRO for the pain project - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Subscribe

Quick facts

BioStock: CombiGene has chosen CRO for the pain project
Tweet this